Methods for quality control of prothrombin time (PT) and activated partial thromboplastin time (APTT) assays using coagulation controls
First Claim
1. A coagulation control suitable for evaluating prothrombin time (PT) or activated partial thromboplastin time (APTT) assays, the coagulation control comprising an abnormal plasma, and an anticoagulant having activity for enhancing the activity of antithrombin III (ATIII) or of heparin co-factor II (HCII) against thrombin or against a clotting factor selected from the group consisting of factors IXa, Xa and XIa.
2 Assignments
0 Petitions
Accused Products
Abstract
Coagulation control compositions suitable for use in connection with PT and/or APTT assays are disclosed along with their methods of preparation and methods of use. Preferred coagulation controls comprise plasma and an anticoagulant having activity for enhancing the activity of antithrombin III (ATIII) or of heparin co-factor II (HCII) against thrombin or against a clotting factor selected from the group consisting of factors IXa, Xa and XIa. The anticoagulant is preferably a glycosaminoglycan such as heparin, a heparin derivative or a heparin analog. The anticoagulant is preferably combined with (1) an abnormal plasma (e.g. activated plasma or factor-deficient plasma) and/or (2) a primate plasma (e.g. human plasma), and a non-primate mammalian plasma (e.g. bovine plasma). In the latter case, the non-primate mammalian plasma is preferably present in the coagulation control composition in an amount of not more than about 12% by volume, relative to total volume.
29 Citations
68 Claims
-
1. A coagulation control suitable for evaluating prothrombin time (PT) or activated partial thromboplastin time (APTT) assays, the coagulation control comprising
an abnormal plasma, and an anticoagulant having activity for enhancing the activity of antithrombin III (ATIII) or of heparin co-factor II (HCII) against thrombin or against a clotting factor selected from the group consisting of factors IXa, Xa and XIa.
-
10. A coagulation control suitable for evaluating prothrombin time (PT) or activated partial thromboplastin time (APTT) assays, the coagulation control comprising a solution comprising
a primate plasma, a non-primate mammalian plasma, and an anticoagulant having activity for enhancing the activity of antithrombin III (ATIII) or of heparin co-factor II (HCII) against thrombin or against a clotting factor selected from the group consisting of factors IXa, Xa and XIa, the concentration of anticoagulant ranging from about 0.01 U/ml to about 0.15 U/ml, where U is heparin-equivalent units.
-
41. A coagulation control suitable for evaluating prothrombin time (PT) or activated partial thromboplastin time (APTT) assays, the coagulation control comprising
primate plasma, non-primate mammalian plasma, and an anticoagulant having activity for enhancing the activity of antithrombin III (ATIII) or of heparin co-factor II (HCII) against thrombin or against a clotting factor selected from the group consisting of factors IXa, Xa and XIa, the concentration of anticoagulant ranging from about 0.1 U/g to about 0.18 U/g on a dry-weight basis where U is heparin-equivalent units.
-
45. A coagulation control suitable for evaluating prothrombin time (PT) or activated partial thromboplastin time (APTT) assays, the coagulation control comprising
human plasma and non-primate mammalian plasma, the ratio of non-primate mammalian plasma to human plasma ranging from about 1:
-
61. A method for preparing a coagulation control suitable for evaluating prothrombin time (PT) or activated partial thromboplastin time (APTT) assays, the method comprising
combining primate plasma, non-primate mammalian plasma and an anticoagulant having activity for enhancing the activity of antithrombin III (ATIII) or of heparin co-factor II (HCII) against thrombin or against a clotting factor selected from the group consisting of factors IXa, Xa and XIa to form a control solution having an anticoagulant concentration ranging from about 0.01 U/ml to about 0.15 U/ml, where U is heparin-equivalent units.
-
63. A method for preparing a coagulation control suitable for evaluating prothrombin time (PT) and activated partial thromboplastin time (APTT) assays, the method comprising
combining human plasma and non-primate mammalian plasma to form a control solution comprising non-primate mammalian plasma in an amount ranging from about 0.5% to about 12% by volume.
-
65. A method for quality control of a prothrombin time (PT) assay system, the method comprising
combining a PT reagent with a coagulation control to form an assay solution, the coagulation control comprising a plasma and an anticoagulant having activity for enhancing the activity of antithrombin III (ATIII) or of heparin co-factor II (HCII) against thrombin or against a clotting factor selected from the group consisting of factors IXa, Xa and XIa, detecting clot formation in the assay solution, and determining the time elapsed from formation of the assay solution to detection of clot formation in the assay solution.
-
66. A method for quality control of a prothrombin time (PT) or an activated partial thromboplastin time (APTT) assay system, the method comprising
combining a PT reagent or an APTT reagent with a coagulation control to form an assay solution, the coagulation control comprising an abnormal plasma and an anticoagulant having activity for enhancing the activity of antithrombin III (ATIII) or of heparin co-factor II (HCII) against thrombin or against a clotting factor selected from the group consisting of factors IXa, Xa and XIa, detecting clot formation in the assay solution, and determining the time elapsed from formation of the assay solution to detection of clot formation in the assay solution.
-
67. A method for quality control of a prothrombin time (PT) or an activated partial thromboplastin time (APTT) assay system, the method comprising
combining a PT reagent or an APTT reagent with a coagulation control solution to form an assay solution, the coagulation control solution comprising primate plasma, non-primate mammalian plasma and an anticoagulant having activity for enhancing the activity of antithrombin III (ATIII) or of heparin co-factor II (HCII) against thrombin or against a clotting factor selected from the group consisting of factors IXa, Xa and XIa, the concentration of anticoagulant in the coagulation control solution ranging from about 0.01 U/ml to about 0.15 U/ml, where U is heparin-equivalent units, detecting clot formation in the assay solution, and determining the time elapsed from formation of the assay solution to detection of clot formation in the assay solution.
-
68. A method for quality control of a prothrombin time (PT) or an activated partial thromboplastin time (APTT) assay, the method comprising
combining a PT reagent or an APTT reagent with a coagulation control to form an assay solution, the coagulation control comprising human plasma and non-primate mammalian plasma, the ratio of non-primate mammalian plasma to human plasma ranging from about 1: - 200 to about 1;
5,detecting clot formation in the assay solution, and determining the time elapsed from formation of the assay solution to detection of clot formation in the assay solution.
- 200 to about 1;
Specification